Physician profile
Peter Heit
NPI 1912952763
$17,379.18
in general payments reported to CMS, 2019-2025
34 companies · $3,526 in 2025
The $3,526 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $1,233 · 2021: $2,604 · 2022: $2,391 · 2023: $2,553 · 2024: $3,040 · 2025: $3,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,103 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,102.93 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,634.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,958.49 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,252.01 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $1,039.49 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $880.39 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $711.61 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $644.41 | 2019-2025 | Livdelzi |
| Aimmune Therapeutics, INC. | $593.10 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $581.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $477.02 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $465.15 | 2020-2023 | |
| Intra-Sana Laboratories | $460.28 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Intercept Pharmaceuticals, INC. | $442.18 | 2020-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $408.16 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $358.84 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $345.91 | 2021-2025 | Qsymia, Pancreaze |
| Ipsen Biopharmaceuticals, INC | $294.47 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $242.19 | 2021-2023 | Talicia |
| Ardelyx, INC. | $239.61 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $226.82 | 2024-2025 | Omvoh |
| Celgene Corporation | $224.35 | 2021-2024 | Zeposia |
| Allergan, INC. | $171.20 | 2019 | |
| Medtronic, INC. | $148.80 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $116.41 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $97.27 | 2021-2024 | Sutab |
| Ironwood Pharmaceuticals, INC | $95.09 | 2020-2024 | |
| Alnylam Pharmaceuticals INC. | $53.85 | 2021-2022 | |
| Shionogi INC | $50.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $34.74 | 2023-2025 | Dupixent |
| Conmed Corporation | $33.97 | 2023 | Airseal |
| Digestive Care, INC. | $33.71 | 2020 | |
| Alfasigma USA, INC. | $29.02 | 2020 | |
| Mallinckrodt Hospital Products INC. | $19.49 | 2020 | |
| Omeros Corporation | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Heit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.